Stock SLNO SOLENO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
42.08 USD -1.29% Intraday chart for Soleno Therapeutics, Inc. +2.24% +4.55%
May. 22 Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 CI
May. 13 Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating MT

Evolution of the average Target Price on Soleno Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1ea5cff14.qPYl1TcJET4zVm6bSXgTibmFoUfhXzNoiFzIKTbi7YA.ka9Eil9dd10LGVjJOz4m_f7H7BaICmJfwxuZUWWrqevKjkGGc3xfekdgOw~9a3b1985451f0b80dfa8fafff00999da

Analyst Recommendations on Soleno Therapeutics, Inc.

Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating MT
Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target MT
Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing MT
Piper Sandler Starts Soleno Therapeutics With Overweight Rating, $93 Price Target MT
Stifel Starts Soleno Therapeutics With Buy Rating, $63 Price Target MT
Oppenheimer Lifts Price Target on Soleno Therapeutics to $47 From $44, Maintains Outperform Rating MT
Oppenheimer Adjusts Soleno Therapeutics Price Target to $44 From $39, Maintains Outperform Rating MT
Wall St slides as rate concerns keep Treasury yields near 16-year peak RE
Cantor Fitzgerald Raises Price Target on Soleno Therapeutics to $35 From $19, Maintains Overweight Rating MT
Oppenheimer Raises Soleno Therapeutics Price Target to $14 Form $8, Maintains Outperform Rating MT
Cantor Fitzgerald Starts Soleno Therapeutics at Overweight With $19 Price Target MT
Oppenheimer Adjusts Soleno Therapeutics PT to $8 From $2 to Better Reflect Recent Reverse Stock Split, Maintains Outperform Rating MT
Oppenheimer Adjusts Soleno Therapeutics Price Target to $2 From $3, Maintains Outperform Rating MT
Oppenheimer Adjusts Soleno Therapeutics' Price Target to $3 From $5, Maintains Outperform Rating MT
History shows stocks can weather rate hike cycle RE
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
42.08 USD
Average target price
68.14 USD
Spread / Average Target
+61.94%
High Price Target
93 USD
Spread / Highest target
+121.01%
Low Price Target
59 USD
Spread / Lowest Target
+40.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Soleno Therapeutics, Inc.

Oppenheimer
Baird
Piper Sandler
Stifel Nicolaus
Cantor Fitzgerald

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SLNO Stock
  4. Consensus Soleno Therapeutics, Inc.